IP Library Granted Patent US 11,648,013
Granted Patent B2
US 11,648,013 · App. 16/952,756 · Granted May 16, 2023

Occlusion device

Inventor: Stephen Griffin (Fremont, CA)
Assignee: Cerus Endovascular Limited
A61B17/12122A61B17/12172A61B17/12177A61B90/39A61B2017/00243A61B2017/00575A61B2090/3966
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,648,013
App. No.
16/952,756
Granted
May 16, 2023
Kind
B2
Abstract

Provided herein is an occlusion device comprising: (a) a substantially solid marker band having an inner and outer diameter, a proximal end, and a distal end; and (b) a resilient mesh body attached within the marker band, wherein the body is a length y, and wherein the body comprises a bolus of additional resilient mesh material of a length x, wherein y is greater than x, and wherein the body extends distally from the marker band having a first delivery shape and a second expandable deployed shape. Also provided herein is a kit comprising the occlusion device disclosed herein and a means for delivery thereof. Methods of manufacture and use of the occlusion device disclosed herein are also disclosed.

Claims (25)

1. An occlusion device comprising:

(a) a marker band having an inner diameter and an outer diameter, a proximal end, and a distal end; and

(b) a resilient mesh body attached within the marker band, the body having a bolus of resilient mesh material and being longer than the bolus, the body further comprising a single layer of resilient mesh circumferentially folded over onto itself to create a dual layer of mesh and having folded over ends of the resilient mesh, all the folded over ends of the dual layer of mesh are attached within the marker, and

(c) the body having a first delivery shape and a second expandable deployed inverted mushroom shape extending distally from the marker band.

2. The occlusion device of claim 1 , wherein the mesh has a density sufficient to function as an endothelial scaffold within a human vessel.

3. The occlusion device of claim 2 , wherein a high mesh density region of the resilient mesh has about 70% or more metal area.

4. The occlusion device of claim 1 , wherein a coil-wound core wire or guide wire of a catheter or micro-catheter is attached inside and at the distal end of the marker band.

5. The occlusion device of claim 1 , wherein the body has an open mesh density for enhanced tissue integration and/or stabilization of the occlusion device.

6. The occlusion device of claim 1 , wherein resilient mesh body and the bolus of additional resilient mesh material are dissimilar metals.

7. The occlusion device of claim 1 , wherein the resilient mesh body is constructed from a super elastic material.

8. The occlusion device of claim 5 , wherein the resilient mesh body is constructed from nitinol.

9. The occlusion device of claim 5 , wherein the resilient mesh body is constructed from DFT platinum core nitinol.

10. The occlusion device of claim 1 , wherein the bolus of resilient mesh material is constructed from a super elastic material.

11. The occlusion device of claim 1 , wherein the marker band is a rigid member.

12. The occlusion device of claim 8 , wherein the bolus is constructed from nitinol.

13. The occlusion device of claim 8 , wherein the bolus is constructed from DFT platinum core nitinol.

14. The occlusion device of claim 1 , wherein the marker band comprises at least one material selected from the group consisting of plastically deformable and shape-memory resilient mesh material, wire braided mesh material, wire braided mesh material, laser cut mesh material.

15. The occlusion device of claim 11 , wherein the rigid member is a ring, or a collar.

16. The occlusion device of claim 1 , wherein the marker band is radiopaque.

17. The occlusion device of claim 1 , comprising a Left Atrial Appendage (LAA) occlusion device.

18. A method for treating or ameliorating Left Atrial Appendage (LAA) in a patient, the method comprising:

i.) delivering to an LAA the occlusion device of claim 1 and

ii.) deploying the occlusion device in the LAA, thereby treating or ameliorating LAA in the patient.

19. The method of claim 18 , which comprises deploying the device through the left atrial space adjacent to the LAA using an electrolytic wire.

20. The method of claim 19 , which comprises deploying the device with a catheter.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2024
From: CERUS ENDOVASCULAR LTD.
To: STRYKER IRELAND TECHNOLOGY LTD.
Reel/Frame 066667/0328 →
RELEASE OF SECURITY INTEREST Recorded May 2, 2023
From: MIDCAP FINANCIAL TRUST
To: CERUS ENDOVASCULAR, INC.; CERUS ENDOVASCULAR LIMITED
Reel/Frame 063515/0943 →
SECURITY INTEREST Recorded Feb 11, 2023
From: CERUS ENDOVASCULAR LIMITED; CERUS ENDOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 062665/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2020
From: GRIFFIN, STEPHEN
To: CERUS ENDOVASCULAR LIMITED
Reel/Frame 054423/0755 →
Continuity (3)
Continuation 16080626
Provisional Application 62307137 · Mar 11, 2016
Related Publication 20210068842A1 · Mar 11, 2021
Cited By (1)
US 12,318,294